19 May 2013
Keywords: Sosei, Vectura, Novartis, Sandoz, QVA149, NVA237, Financial update
Article | 10 May 2010
Swiss drug major Novartis has commenced a Phase III clinical progam with QVA149, a once-daily, dry powder bronchodilator for inhalation ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 May 2010
11 May 2010
17 May 2013
© 2013 thepharmaletter.com